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Background. Prediction of survival in patients diagnosed with lung cancer remains problematical. The aim of the present study was
to examine the clinical utility of an established objective marker of the systemic inflammatory response, the Glasgow Prognostic
Score, as the basis of risk stratification in patients with lung cancer. Methods. Between 2005 and 2008 all newly diagnosed lung
cancer patients coming through the multidisciplinary meetings (MDTs) of four Scottish centres were included in the study. The
details of 882 patients with a confirmed new diagnosis of any subtype or stage of lung cancer were collected prospectively. Results.
The median survival was 5.6 months (IQR 4.8–6.5). Survival analysis was undertaken in three separate groups based on mGPS
score. In the mGPS 0 group the most highly predictive factors were performance status, weight loss, stage of NSCLC, and palliative
treatment offered. In the mGPS 1 group performance status, stage of NSCLC, and radical treatment offered were significant. In
the mGPS 2 group only performance status and weight loss were statistically significant. Discussion. This present study confirms
previous work supporting the use of mGPS in predicting cancer survival; however, it goes further by showing how it might be used
to provide more objective risk stratification in patients diagnosed with lung cancer.
1. Introduction
Within Scotland lung cancer remains the commonest cause
of cancer related death [1]. The prognosis is bleak with the
median survival in advanced disease around four months
from diagnosis [1]. Survival compares unfavourably with
other European countries and the USA [1, 2]. It has often
been felt that the Scottish lung cancer population has more
comorbidity with poorer performance status thus presenting
fewer tolerable therapeutic options.
It is difficult to quantify the complex nature of patient
frailty to provide a degree of objective assessment of fitness
[3] and as a result prediction of survival in patients diagnosed
with lung cancer remains problematical. Currently, prognosis
is based upon a combination of stage of disease and per-
formance status although other factors such as weight loss
have been identified in the advanced cancer setting [4–6].
However, these host factors (weight loss and performance
status) included in clinical decisions are recognised to be
subjective in nature.
Recent work shows that the effect of systemic inflamma-
tion is detrimental in terms of outcome in cancer in general
[7, 8] and in lung cancer specifically [9–16].The combination
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Table 1: The Glasgow Prognostic Scores (online only).
Score
Glasgow Prognostic Score (GPS)
CRP ≤10mg/L and albumin ≥35 g/L 0
CRP >10mg/L or albumin <35 g/L 1
CRP >10mg/L and albumin <35 g/L 2
Modified Glasgow Prognostic Score (mGPS)
CRP ≤10mg/L and albumin ≥35 g/L 0
CRP ≤10mg/L and albumin <35 g/L 0
CRP >10mg/L 1
CRP >10mg/L and albumin <35 g/L 2
of C-reactive protein and albumin when combined to calcu-
late themodifiedGlasgowPrognostic Score (Table 1) has been
previously validated as an independent predictor of survival
[17].
The aim of the present study was to examine the clinical
utility of this established objective marker of the systemic
inflammatory response, the modified Glasgow Prognostic
Score (mGPS), as the basis of risk stratification in patients
with lung cancer.
2. Patients and Methods
Four Scottish centres were included in the study: Aberdeen,
Glasgow (Stobhill), Inverclyde, andWest Fife. Over a defined
period from 2005 to 2008 all newly diagnosed lung cancer
patients coming through the regionalmultidisciplinarymeet-
ings (MDTs) were included in the study. In total the details of
882 patients were collected prospectively.
At the time of the patient discussion at the MDT
annoymised details were entered into a specifically designed
Microsoft Access database. Patient demographics and base-
line characteristics (age, sex, postcode, and smoking history),
PS (at time of presentation in addition to that six months
prior to attendance as estimated by clinicians on questioning
patients about fitness), weight loss, laboratory parameters
(C-reactive protein, albumin, and ventilatory function),
tumour stage and histology, and primary treatment proposed
by the MDT were all recorded. If the treatment proposed
varied from the 2005 Scottish Intercollegiate Guidelines
Network (SIGN) guidelines [18] on lung cancer management
the reasons why were also recorded (i.e., age, poor PS,
comorbidity, size of tumour, etc.). All four MDTs had input
from an oncologist and thoracic surgeon and thus we could
be confident of accuracy of the clinicalmanagement decision.
Details of the study design have previously been published
[19].
Information on date of death was obtained via survival
analysis undertaken by the Information Service Division
(ISD) of NHS Scotland. Death records were complete until
1 June 2011, which served as the censor date for those alive.
2.1. Socioeconomic Status. Information on patients’ individ-
ual educational or occupational social class was not available,
and postcode of residence was used to identify the 2006
Table 2: Baseline characteristics of patients with lung cancer (𝑛 =
882).
Parameter
Age (years) 72 (31–94) years
Sex
Male 487 (55%)
Female 395 (45%)
Smoking
Ever smoked 94%
Mean pack (years) 44 years
Centre
Aberdeen 294 (34%)
Fife 132 (15%)
Stobhill 245 (32%)
Inverclyde 161 (19%)
Deprivation (quintile)
Most deprived 267 (30%)
2.00 127 (14%)
3.00 251 (29%)
4.00 175 (20%)
Most affluent 62 (7%)
Performance status
0 101 (11%)
1 312 (35%)
2 285 (32%)
3 154 (17%)
4 30 (3%)
Stage
NSCLC I 66 (7%)
NSCLC II 43 (5%)
NSCLC St IIIa 48 (5%)
NSCLC St IIIb 140 (16%)
NSCLC St IV 234 (26%)
SCLC limited 33 (4%)
SCLC extensive 82 (9%)
No histology 210 (24%)
Treatment
Radical 193 (27%)
Palliative 533 (73%)
mGPS
0 213 (24%)
1 290 (32%)
2 210 (24%)
Missing data 169 (19%)
12-month survival rate % (SE) 30% (2)
Scottish Index of Multiple Deprivation (SIMD) ranking as a
proxy indicator of their socioeconomic circumstances [20].
The 2006 SIMD is a validated area-based index that uses 37
indicators in seven domains to rank 6505 small geographic
areas in Scotland (data zones) from 1 (most deprived) to
6505 (least deprived). These can be subsequently grouped
into quintiles, and we used Scottish national quintiles.
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Table 3: The relationship between the mGPS and clinicopathological characteristics in patients with lung cancer.
Demographic mGPS 𝑃 value (chi-square test)
0 (𝑛 = 213) 1 (𝑛 = 290) 2 (𝑛 = 218)
Age
<60/60–69/70–79/≥80 years 33/71/89/28 44/87/119/54 34/57/91/49 0.064
Sex
Male/female 115/108 174/130 133/98 0.201
Centre
Aber/Fife/Stob/Inver 98/10/77/38 146/25/66/67 43/16/126/46 <0.001
Deprivation
Most-least (quintile) 68/24/71/39/21 75/47/75/77/30 111/21/70/20/9 <0.001
Smoke (pack years)
NS/<20/20–60/>60 21/24/126/37 11/33/177/69 13/21/128/57 0.014
Performance status
0/1/2/3/4 42/96/60/22/3 26/130/105/40/3 5/51/88/66/21 <0.001
Weight loss (%)
0/<5/5–10/>10 147/24/12/38 146/36/13/109 79/45/33/73 <0.001
FEV1 (%)
<80/61–80/40–60/<40 138/31/45/7 181/48/53/22 130/33/47/17 0.126
Local symptoms
No/yes 36/127 18/222 29/137 0.246
Tumour stage of NSCLC
I/II/IIIa/IIIb/IV 32/11/7/38/38 15/19/20/56/84 7/5/12/36/79 <0.001
Tumour stage of SCLC
Limited/extensive 13/21 10/32 8/18 0.471
Treatment
Radical treatment
Surgery/RT/no active 26/9/38 17/15/43 4/2/18 <0.001
Palliative treatment
Chemo/RT/No active 63/27/49 107/58/55 50/49/75 <0.001
Survival
Alive/dead 34/181 16/274 8/211 0.003
12-month survival % (SE) 46 (4) 16 (2) 14 (3) <0.001
2.2. GPS/mGPS. A venous blood sample was obtained at
diagnosis for measurement of CRP concentration and albu-
min. The coefficient of variation for these methods over the
range of measurement was less than 5%, as established by
routine quality control procedures.The GPS was constructed
as previously described (Table 1) [21, 22]. In brief, CRP more
than 10mg/L and albumin less than 35 g/dL were each given
a score of 1. The GPS was calculated as 0, 1, or 2. Since
hypoalbuminaemia alone in the absence of an increased CRP
level did not confer a poorer cancer-specific survival in all
patients with cancer [8, 22], the GPS was modified to assign a
score of 0 in patients with hypoalbuminaemia alone (Table 1)
[23].
A number of recent studies have supported the use
of mGPS in predicting outcome both in lung cancer and
other tumour types [9–17]. As such it was our intention to
stratify the group by mGPS and then analyse the impact of
more conventional staging methods such as TNM stage and
performance status.
2.3. Ethics. The audit was discussed with the local ethics
committee, and since it was classed as a health service clinical
practice audit, formal ethical approval was deemed not to be
necessary.
2.4. Statistics. All statistical testing was conducted at the 5%
level so 95% confidence intervals (CI) are reported through-
out. Unless otherwise stated, medians and interquartile range
(IQR) are used. The survival time defined as the number of
months from study entry until death or if alive at follow-up
date was calculated. Univariate survival analysis was carried
out using the Kaplan-Meier method and the log rank test.
Survival analysis was carried out using Cox’s proportional-
hazards model and hazard ratios (HR) were calculated.
Multivariate survival analysis was performed using a stepwise
backward procedure to derive a final model of the variables
that had a significant independent relationship with survival.
To remove a variable from the model, the corresponding 𝑃
value had to be >0.10.
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All patients
Surgery
54 patients
Palliative 
chemotherapy
162 patients
Palliative 
radiotherapy
158 patients
Excluded due to 
missing survival data
SCLC 
112 patients
No active 
treatment
261 patients
Radical
radiotherapy
76 patients
(n = 882)
(n = 59)
Figure 1: Flow chart of patient selection process.
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Figure 2: The relationship between GPS (0–2, from top to bottom)
and survival. GPS 0 versus 1 (log rank 𝑃 < 0.001), GPS 1 versus 2
(log rank 𝑃 < 0.001).
Statistical analyses were performed using SPSS v19.0
(SPSS Inc., Chicago, IL).
3. Results
In total, 882 patients from a number of different treatment
groups were included in the study, comprising 297 from
Aberdeen, 136 from West Fife, 285 from Glasgow, and 164
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Figure 3:The relationship betweenmGPS (0–2, from top to bottom)
and survival. mGPS 0 versus 1 (log rank 𝑃 < 0.001), mGPS 1 versus
2 (log rank 𝑃 < 0.001).
from Inverclyde composing; 59 patients were excluded from
the study due to missing survival data (Figure 1). Baseline
characteristics are shown in Table 2. The median age of
participants was 72 years old. The majority were male,
current or ex-smokers, and of good performance status with
advanced disease and had treatment with palliative intent.
Of the patients 24% were diagnosed on the basis of
clinical examination and radiological investigations alone
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Table 4: The relationship between parameters and survival in patients with mGPS = 0 (𝑛 = 213).
Parameter Patients Univariate Multivariate
𝑁 HR (95% CI) 𝑃 value HR (95% CI) 𝑃 value
Age
<60/60–69/70–79/≥80 years 33/71/89/28 1.16 (0.98–1.37) 0.077 —
Sex
Male 115 1 — — —
Female 108 0.81 (0.61–1.09) 0.169 — —
Centre
Aberdeen 98 1 0.068 — —
Fife 10 2.72 (1.40–5.29) — — —
Stobhill 77 1.00 (0.72–1.41) — — —
Inverclyde 38 1.13 (0.75–1.70) — — —
Deprivation (most deprived = 1, least deprived = 5)
1/2/3/4/5 68/24/71/39/21 0.94 (0.85–1.05) 0.299 — —
Smoking history (NS = never smoker, otherwise pack years)
NS/<20/20–60/>60 21/24/126/37 0.93 (0.77–1.12) 0.467 — —
Performance status
0/1/2/3/4 42/96/60/22/3 1.76 (1.47–2.11) <0.001 1.69 (1.39–2.06) <0.001
Weight loss (% body weight)
0/<5/5–10/>10 147/24/12/38 1.21 (1.08–1.37) 0.002 1.18 (1.04–1.33) 0.009
FEV1 (%)
>80/80–60/59–40/<40 138/31/45/7 0.94 (0.80–1.12) 0.515 — —
Local symptoms
No/yes 36/127 1.38 (0.91–2.09) 0.124 — —
Stage
NSCLC
I/II/IIIa/IIIb/IV 32/11/7/38/38 1.38 (1.25–1.53) <0.001 1.06 (1.01–1.23) 0.017
SCLC
Limited/extensive 13/21 1.05 (0.97–1.14) 0.228 — —
Treatment
Radical
BSC/surgery/RT 37/26/8 0.61 (0.48–0.78) 0.001 — —
Palliative
Chemo/RT/BSC 59/27/47 1.22 (1.01–1.46) 0.039 1.30 (1.08–1.55) 0.004
and without histological evidence. This compares favourably
with the National Lung Cancer Audit data [24], which had a
median rate of 37% of patients who did not have histological
confirmation of lung cancer.
Most had an elevated mGPS. The median followup for
survivors was 24.5 months (4.6–40.8). The median overall
survival was 5.6months (4.8–6.5).The 12-month survival rate
was 30% (SE 2%).
Survival analysis using both GPS and mGPS was under-
taken (Figures 2 and 3). Both were highly significantly
associated with survival. Since the mGPS has been most
extensively validated and readily extrapolated from previous
work using C-reactive protein alone [7, 17], it was used in the
remainder of the analysis and to stratify the three groups.
The relationship between the mGPS and clinicopatho-
logical characteristics is shown in Table 3. There were 213
patients in the mGPS score of 0 group, 290 patients in
the mGPS score of 1 group, and 218 patients in the mGPS
score of 2 group. The mGPS was associated with increasing
deprivation (𝑃 < 0.001), pack years smoking (𝑃 < 0.001),
poorer performance status (𝑃 < 0.001), more weight loss
(𝑃 < 0.001),more advanceddisease (𝑃 < 0.001),more radical
treatment (𝑃 < 0.001), and poorer survival (𝑃 < 0.001).
The relationship between the clinicopathological charac-
teristics and survival in patients with an mGPS of 0 is shown
in Table 4. The median survival was 13.2 (11.2–18.9) months.
On univariate survival analysis, performance status (𝑃 <
0.001), weight loss (𝑃 < 0.01), stage of NSCLC (𝑃 < 0.001),
radical treatment offered (𝑃 < 0.01), and palliative treatment
offered (𝑃 < 0.05) were significantly associated with survival.
On multivariate analysis, performance status (HR 1.69, 95%
CI 1.39–2.06, and 𝑃 < 0.001), weight loss (HR 1.18, 95% CI
1.04–1.33, and 𝑃 = 0.009), stage of NSCLC (HR 1.06, 95% CI
1.01–1.23, and𝑃 = 0.017) and palliative treatment offered (HR
1.30, 95% CI 1.08–1.55, and 𝑃 = 0.004) were independently
associated with survival.
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Table 5: The relationship between parameters and survival in patients with mGPS = 1 (𝑛 = 290).
Parameter Patients Univariate Multivariate
𝑁 HR (95% CI) 𝑃 value HR (95% CI) 𝑃 value
Age
<60/60–69/70–79/≥80 33/71/89/28 1.24 (1.09–1.40) 0.001 — —
Sex
Male 174 1 0.171 — —
Female 130 0.84 (0.66–1.08) — — —
Centre
Aberdeen 145 1 0.425 — —
Fife 23 0.89 (0.55–1.43) — — —
Stobhill 55 0.99 (0.72–1.36) — — —
Inverclyde 67 1.23 (0.92–1.66) — — —
Deprivation (quintile) (most deprived = 1, least deprived = 5)
1/2/3/4/5 75/47/75/77/30 0.99 (0.90–1.08) 0.777 — —
Smoking history (NS = never smoker, otherwise pack years)
NS/<20/20–60/>60 11/33/177/69 1.02 (0.86–1.22) 0.792 — —
Performance status
0/1/2/3/4 26/130/105/40/3 1.83 (1.57–2.14) <0.001 1.81 (1.55–2.13) <0.001
Weight loss (% body weight)
0/<5/5–10/>10 181/48/53/22 1.15 (1.06–1.25) 0.001 — —
FEV1 (%)
>80/80–60/59–40/<40 138/31/45/7 0.94 (0.83–1.06) 0.313 — —
Local symptoms
No/yes 18/222 1.60 (0.91–2.80) 0.105 — —
Stage
NSCLC
I/II/IIIa/IIIb/IV 15/19/20/56/84 1.31 (1.19–1.45) <0.001 1.08 (1.03–1.13) 0.002
SCLC
Limited/extensive 10/32 0.51 (0.23–1.11) 0.091 — —
Treatment
Radical
BSC/surgery/RT 43/17/15 0.55 (0.41–0.72) <0.001 0.70 (0.52–0.94) 0.017
Palliative
Chemo/RT/BSC 107/58/55 1.07 (0.90–1.26) 0.436 — —
The relationship between the clinico-pathological charac-
teristics and survival in patients with an mGPS of 1 is shown
in Table 5. The median survival was 6.1 (4.9–7.3) months.
On univariate survival analysis, decreased age (𝑃 < 0.01),
performance status (𝑃 < 0.001), weight loss (𝑃 < 0.01),
stage of NSCLC (𝑃 < 0.001), and radical treatment offered
(𝑃 < 0.001) were significantly associated with survival. On
multivariate analysis, performance status (HR 1.81, 95% CI
1.55–2.13, and 𝑃 < 0.001), stage of NSCLC (HR 1.08, 95% CI
1.03–1.13, and 𝑃 < 0.01) and radical treatment offered (HR
0.70, 95% CI 0.52–0.94, and 𝑃 < 0.05) were independently
associated with survival.
The relationship between the clinico-pathological charac-
teristics and survival in patients with an mGPS of 2 is shown
in Table 6. The median survival was 2.1 (1.5–2.7) months. On
univariate survival analysis, centre (𝑃 < 0.01), performance
status (𝑃 < 0.001), weight loss (𝑃 < 0.001), stage of NSCLC
(𝑃 < 0.001), and radical treatment offered (𝑃 < 0.01)
were significantly associated with survival. On multivariate
analysis, only performance status (HR 1.44, 95% CI 1.21–1.71,
and 𝑃 < 0.001) and weight loss (HR 1.13, 95% CI 1.00–1.28,
and 𝑃 < 0.05) were independently associated with survival.
The relationship betweenmGPS, performance status, and
survival at 1 year is shown in Table 7.When used in combina-
tion survival at 1 year varied from 72% (mGPS 0, PS 0) to 6%
(mGPS 2, PS 3). The numbers in the PS 4 subgroup were too
small to calculate accurately a survival rate.
The relationship between mGPS, TNM stage (NSCLC
patients only), and survival at 1 year is shown in Table 8.
Survival varied from 69% (mGPS 0, Stage I NSCLC) to 2%
(mGPS 2, Stage IV NSCLC).
To stratify for stage, the relationship between mGPS and
PS and survival at 3 months for those patients with advanced
NSCLC (St IIIb/IV) is shown in Table 9.
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Table 6: The relationship between parameters and survival in patients with mGPS = 2 (𝑛 = 218).
Parameter Patients Univariate Multivariate
𝑁 HR (95% CI) 𝑃 value HR (95% CI) 𝑃 value
Age
<60/60–69/70–79/≥80 34/57/91/49 1.13 (0.98–1.30) 0.084 — —
Sex
Male 133 1 0.136 — —
Female 98 0.81 (0.61–1.07) — — —
Centre
Aberdeen 43 1 0.002 — —
Fife 16 1.71 (0.95–3.06) — — —
Stobhill 114 0.64 (0.45–0.92) — — —
Inverclyde 45 0.88 (0.57–1.35) — — —
Deprivation (quintile) (most deprived = 1, least deprived = 5)
1/2/3/4/5 111/21/70/20/9 1.05 (0.94–1.17) 0.408 — —
Smoking history (NS = never smoker, otherwise pack years)
NS/<20/20–60/>60 13/21/128/57 0.83 (0.69–1.00) 0.062 — —
Performance status
0/1/2/3/4 5/51/88/66/21 1.51 (1.30–1.76) <0.001 1.44 (1.21–1.71) <0.001
Weight loss (% body weight)
0/<5/5–10/>10 79/45/33/73 1.25 (1.11–1.40) <0.001 1.13 (1.00–1.28) 0.047
FEV1 (%)
>80/80–60/59–40/<40 130/33/47/17 0.88 (0.77–1.01) 0.073 — —
Local symptoms
No/Yes 29/137 1.51 (0.98–2.33) 0.063 — —
Stage
NSCLC
I/II/IIIa/IIIb/IV 7/5/12/36/79 1.32 (1.15–1.50) <0.001 — —
SCLC
Limited/extensive 8/18 1.01 (0.91–1.12) 0.826 — —
Treatment
Radical
BSC/surgery/RT 18/2/4 0.52 (0.33–0.83) 0.006 — —
Palliative
Chemo/RT/BSC 50/49/75 0.92 (0.78–1.10) 0.364 — —
Survival varied from 100% (mGPS 0, PS 0) to 23%
(mGPS 2, PS 3).Thenumber of patients in the PS 4 groupwas
too small to accurately calculate survival.
This groupwas then further stratified to take into account
the treatment offered. The relationship between mGPS and
PS at 3 months for those patients with advanced NSCLC
(St IIIb/IV) undergoing palliative chemotherapy is shown in
Table 10. Survival varied from 92% (mGPS 0, PS 1) to 50%
(mGPS 2, PS 2). The numbers of patients in the PS 0 and 4
groups were too small to accurately calculate survival.
4. Discussion
The results of the present study show for the first time
that, in a large cohort of patients with lung cancer and
using the mGPS as an objective basis for the prediction of
survival, significant factors associated with survival varied
significantly. Only performance status and to a lesser extent
Table 7: The relationship between mGPS and PS and 12-month
survival rate (%, SE).
PS mGPS Total numberof patients0 1 2
0 72% (7) 50% (10) 20% (18) 71
1 65% (5) 31% (4) 30% (7) 259
2 49% (7) 19% (4) 16% (4) 245
3 9% (6) 5% (4) 6% (3) 122
4 NC NC NC 20
Total number
of patients 212 290 218 —
NC: not calculated where𝑁 < 10.
tumour stage were consistently shown to have independent
prognostic value. Furthermore, the combination of themGPS
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Table 8: The relationship between mGPS and TNM stage (NSCLC
only) and 12-month survival rate (%, SE).
Stage mGPS Total numberof patients0 1 2
I 69% (19) 28% (12) NC 62
II 37% (14) 17% (9) NC 47
IIIa 20% (13) 42% (10) 0% 53
IIIb 20% (6) 6% (3) 14% (5) 154
IV 5% (3) 4% (2) 2% (2) 261
Total number
of patients 153 225 173 —
NC: not calculated where𝑁 < 10.
Table 9: The relationship between mGPS and PS and 3-month
survival rate (%, SE) in patients with TNM stage IIIb/IV NSCLC
(𝑛 = 374).
PS mGPS Total numberof patients0 1 2
0 100% (0) 92% (8) 100% (0) 28
1 94% (4) 73% (6) 55% (9) 119
2 65% (11) 62% (7) 43% (8) 105
3 NC 29% (11) 23% (8) 55
4 NC NC NC 7
Total number
of patients 61 134 111 —
NC: not calculated where𝑁 < 10.
Table 10: The relationship between mGPS and PS and 3-month
survival rate (%, SE) in patients with TNM stage IIIb/IV NSCLC
and receiving palliative chemotherapy (𝑛 = 138).
PS mGPS Total numberof patients0 1 2
0 NC NC NC 13
1 92% (7) 74% (8) 54% (14) 60
2 NC 69% (12) 50% (16) 33
3 NC NC NC 12
4 NC NC NC 0
Total number
of patients 27 61 30 —
NC: not calculated where𝑁 < 10.
with either performance status or tumour stage effectively
stratified the likely outcome in these patients. Therefore, this
simple scheme based on objective criteria provides a new
readily applicable approach to the routine clinical evaluation
of patients with lung cancer.
In the present study it was of interest that weight loss,
a well recognised poor prognostic factor, was inconsistently
prognostic when included in the analysis with mGPS and
performance status. This may suggest that much of the
prognostic value of weight loss is attributable to the activation
of the systemic inflammatory response and to the progressive
loss of lean tissue leading to nutritional and functional decline
[7]. Indeed, activation of the systemic inflammatory response
resulted in a marked reduction in median survival of 13
months (mGPS 0) to 2 months (mGPS 2) independent of
treatment received. This would suggest that the allocation
of treatment was suboptimal and it may be that treatment
allocated on a more objective scheme as proposed above
will result in improved outcomes in all patients. For exam-
ple, in those patients with mGPS of 2, neither stage nor
treatment had independent prognostic value and therefore it
would appear that such poor prognosis patients derive little
benefit from standard anticancer treatment. In particular
a very honest appraisal of both benefits and toxicities of
any treatment should be made with the patient irrespective
of their tumour stage [25]. However it must be noted
that the very small numbers of patients in these groups
(e.g., only 2 patients underwent surgery and 4 underwent
radical radiotherapy) make it very difficult to interpret and
further studies looking only at radically treatable patients are
advised.
The relationship between poor survival and systemic
inflammation (the mGPS) remains poorly understood, but it
is likely to represent an objectivemarker of the chronic activa-
tion of the innate immune response with the consequent up-
regulation of proinflammatory cytokines and growth factors
and the resultant cancer cachexia [26–31].
It is clear that, in Scotland, lung cancer continues to confer
a very poor outcomewith amedian life expectancy of approx-
imately 5 months. Even in early disease (TNM I/II NSCLC),
with patients undergoing radical treatment with an expec-
tation of cure (10–15% of total number of patients within
Scotland [32]) the 5-year survival is only around 30–60%
[32]. The advent of more advanced imaging modalities such
as PET-CT [18] has improved detection of occult metastasis
leading to stage migration and less patients undergoing
futile radical local treatment. Nevertheless, the present results
highlight the importance of also staging the host systemic
inflammatory response. The mGPS is a simple, cheap, and
reproducible prognostic tool that has been shown to be a
rational starting point for such work.
Since the initial work, a decade ago the combination
of C-reactive protein and albumin, the Glasgow Prognostic
Score (GPS/mGPS), has been shown to have independent
prognostic value in more than 60 studies (>30,000 patients
with cancer).This prognostic value has been demonstrated in
a variety of clinical scenarios, in particular primary operable
cancer [17].
A more recent study of apporximately 2,500 patients [33]
and this present study have demonstrated that the mGPS
has also clinical utility, together with performance status, in
patients with advanced cancer.
In conclusion, the results of the present study confirm
the independent prognostic value of the mGPS. In addition,
it demonstrates the clinical utility of the mGPS combined
with performance status to provide more objective risk
stratification in patients diagnosed with lung cancer.
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